Efficacy and mechanism of electroacupuncture on insulin resistant polycystic ovary syndrome.
10.13703/j.0255-2930.20190903-k0003
- Author:
Li-Qing YU
1
;
Lian-Ying CAO
1
;
Jing XIE
2
;
Yin SHI
3
;
Li-Yan ZHOU
4
;
Tian-Feng HE
4
;
Xiao-Yan CHU
4
Author Information
1. Acupuncture- Moxibustion Department, Shanghai Tianshan Hospital of TCM, Shanghai 200051, China.
2. Gynecology Department, Shanghai Tianshan Hospital of TCM, Shanghai 200051, China.
3. Outpatient Department of Shanghai Institute of Acupuncture-Moxibustion and Meridians.
4. Department of Acupuncture and Moxibustion, Shanghai Jiading Hospital of TCM.
- Publication Type:Journal Article
- Keywords:
electroacupuncture (EA);
insulin resistance (IR);
lipid metabolism;
polycystic ovary syndrome (PCOS);
randomized controlled trial (RCT)
- MeSH:
Acupuncture Points;
Electroacupuncture;
Female;
Humans;
Insulin Resistance;
Polycystic Ovary Syndrome;
therapy
- From:
Chinese Acupuncture & Moxibustion
2020;40(4):379-383
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the therapeutic effect and partial mechanism of electroacupuncture (EA) for patients with insulin resistance (IR) polycystic ovary syndrome (PCOS).
METHODS:Seventy patients with IR-PCOS were randomly divided into an EA group (36 cases, 5 cases dropped off) and a medication group (34 cases, 4 cases dropped off). The patients in the medication group were treated with oral administration of metformin hydrochloride, 500 mg each time, twice a day. The patients in the EA group were treated with EA (continuous wave, 2 Hz of frequency) at Zusanli (ST 36), Zhongwan (CV 12), Qihai (CV 6), Yishu (EX-B 3), Shenshu (BL 23), Pishu (BL 20), Ciliao (BL 32) for 30 min, three times a week. One menstrual cycle or 4 weeks were taken as a course of treatment, and 3 continuous courses were given. The follow-up was 3 months. The lipid metabolism indexes of triacylglycerol (TG), total cholesterol (TC), high-density lipoprotein (HDL) and low-density lipoprotein (LDL), homeostasis model assessment-insulin resistance index (HOMA-IR) and testosterone (T) in serum were compared before and after treatment, and the clinical effects of the two groups were evaluated during the follow-up.
RESULTS:The total effective rate was 67.7% (21/31) in the EA group and 60.0% (18/30) in the medication group, with no significant difference between the two groups (>0.05). After treatment, the levels of serum T, HOMA-IR, LDL, TG and TC were decreased significantly in the two groups (<0.01, <0.05), and HDL was increased significantly (<0.01); the levels of TC in the EA group after treatment was lower than that in the medication group (<0.05).
CONCLUSION:EA may adjust some dyslipidemia in patients to correct IR and improve endocrine disorder of PCOS, which had superior/similar effects to metformin.
